Indiana
Requires Coverage of Comprehensive Biomarker Testing
Yes
Highlighted Disparity
Cancer data are not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Lung Cancer Rates
New Cases:
- Cancer data are not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2020 and 2021.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) is 28.4% nationally. Indiana is one of the 4 states for which survival data is not available as they do not track cases after diagnosis.
Early Diagnosis:
- The early diagnosis rate is not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Lung Cancer Treatment
Surgical Treatment:
- Nationally, 20.7% of cases undergo surgery as part of the first course of treatment. Data on surgery as part of the first course of treatment is not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Biomarker Coverage:
- Indiana was one of the 15 states that required insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2024.
Lack of Treatment:
- Nationally, 20.9% of cases receive no treatment. Data on surgery as part of the first course of treatment is not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Screening
Screening for High Risk:
- In Indiana, 16.9% of those at high risk were screened, which was not significantly different than the national rate of 16.0%.
- It ranks 20th among all states, placing it in the average tier.
Prevention
Tobacco Use:
- The smoking rate in Indiana is 16.2% and significantly higher than the national rate of 12.9%.
- It ranks 43rd among all states, placing it in the below average tier.
Radon:
- In Indiana, 40.2% of radon tests results were at or above the action level recommended by EPA.
- It ranks 40th among all states, placing it in the below average tier.
Racial & Ethnic Disparities
Black individuals:
- Lung cancer rates are not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Latino individuals:
- Lung cancer rates are not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Asian Americans or Pacific Islanders:
- Lung cancer rates are not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Indigenous Peoples:
- Lung cancer rates are not available for Indiana due to the impact of COVID-19 on cancer surveillance in 2021.
Summary
Early diagnosis data is not available for Indiana. When this rate increases, we can anticipate that the surgery rate would increase, as surgery is often the recommended treatment for those diagnosed at an earlier stage. In addition, when cases are found earlier, we would expect the five-year survival rate to increase.
Indiana was one of the states that required insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Page last updated: November 12, 2024